JPH09285267A - Baby food containing nucleotide for improving balance of n-6 series/n-3 series fatty acid - Google Patents
Baby food containing nucleotide for improving balance of n-6 series/n-3 series fatty acidInfo
- Publication number
- JPH09285267A JPH09285267A JP8126332A JP12633296A JPH09285267A JP H09285267 A JPH09285267 A JP H09285267A JP 8126332 A JP8126332 A JP 8126332A JP 12633296 A JP12633296 A JP 12633296A JP H09285267 A JPH09285267 A JP H09285267A
- Authority
- JP
- Japan
- Prior art keywords
- monophosphate
- cholesterol
- dha
- oil
- arachidonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、ｎ−６系列／ｎ−
３系列脂肪酸バランス改善ヌクレオチド含有乳児用食品
に関し、更に詳細には、生体内にてアラキドン酸及びド
コサヘキサエン酸（ＤＨＡ）を増加させ、なおかつ血漿
コレステロールを減少させることなく保存せしめるヌク
レオチドを配合してなる乳児用食品に関するものであ
る。したがって、本発明によれば、乳児期にヌクレオチ
ドと魚油等の油脂を一緒に摂取することにより、生体内
のｎ−３系列脂肪酸であるドコサヘキサエン酸（ＤＨ
Ａ）だけでなく、ｎ−６系列脂肪酸であるアラキドン酸
をもバランスよく増加することができ、さらに、乳児期
に必要とされる血漿ＬＤＬ−コレステロールをも増加さ
せることができるという著効を奏するものである。TECHNICAL FIELD The present invention relates to an n-6 series / n-
The present invention relates to a baby food containing 3 series fatty acid balance-improving nucleotides, more specifically, an infant containing a nucleotide capable of increasing arachidonic acid and docosahexaenoic acid (DHA) in vivo and preserving plasma cholesterol without decreasing it. It relates to food products. Therefore, according to the present invention, by ingesting nucleotides and fats and oils such as fish oil together in infancy, docosahexaenoic acid (DH), which is an n-3 series fatty acid in vivo, is obtained.
Not only A), but also arachidonic acid, which is an n-6 series fatty acid, can be increased in a balanced manner, and further plasma LDL-cholesterol required in infancy can be increased. It is a thing.
【０００２】[0002]
【従来の技術】ＤＨＡは、ｎ−３系列の多価不飽和脂肪
酸であって、日本人母乳中には、脂肪酸組成として０．
６３±０．２４％含まれており（米久保他、小児保健研
究、46、349（1987））、乳児の脳や網膜中の脂質成分
としてこれらの発達の上で重要な役割を果している（Ka
nazawa他：Lipids 1991；26：53-57）。そして、このよ
うな重要性に鑑み、ＤＨＡを強化した調製粉乳が現実に
市販されている。2. Description of the Related Art DHA is an n-3 series polyunsaturated fatty acid and has a fatty acid composition of 0.
63 ± 0.24% (Yonekubo et al., Children's Health Study, 46, 349 (1987)) and plays an important role in these developments as lipid components in the brain and retina of infants ( Ka
nazawa et al .: Lipids 1991; 26: 53-57). And, in view of such importance, formula powder with enhanced DHA is actually commercially available.
【０００３】一方、動物の成長や皮膚への影響から、従
来、必須脂肪酸はｎ−６系列の多価不飽和脂肪酸である
リノール酸だけであると考えられてきたが、アラキドン
酸も、胎児及び新生児の発育や、生体でのエイコサノイ
ドとしての役割又は膜脂質における構造機能に関係して
発育促進効果を有することなどから、生体にとって必須
な脂肪酸であることが認められてきた（Crawford他：Th
e role of Rats in Human Nutrition；edited by Vergr
oessen and Crawford, Academic Press, 1989）。しか
しながら、アラキドン酸を強化した育児用調製乳は市販
されていないのが現状である。On the other hand, from the viewpoint of animal growth and skin effects, it has hitherto been considered that linoleic acid, which is a polyunsaturated fatty acid of the n-6 series, is the only essential fatty acid. It has been recognized that it is an essential fatty acid for living organisms because it has a growth-promoting effect in relation to neonatal development, the role as eicosanoids in the living body, or the structural function of membrane lipids (Crawford et al .: Th.
e role of Rats in Human Nutrition ； edited by Vergr
oessen and Crawford, Academic Press, 1989). However, at present, infant formula containing arachidonic acid fortified is not commercially available.
【０００４】そして、このアラキドン酸に関しては、Ｄ
ＨＡを魚油の形で強化した調製粉乳で哺育された低生体
重児の赤血球膜リン脂質中のＤＨＡレベルは母乳栄養児
並みになるものの、アラキドン酸レベルは母乳栄養児よ
りも下回る傾向であると指摘されている（大元：日本小
児科学会雑誌 1990；94：224-234）。また、魚油とコ
レステロールが強化された系では、血漿中及び組織中の
アラキドン酸の含量低下が観察されている（Garg他：Li
pids 1989；24；226-270）。[0004] With regard to this arachidonic acid, D
Although DHA levels in erythrocyte membrane phospholipids of low-birth weight infants fed with formula powder enriched with HA in the form of fish oil are similar to those of breast-fed infants, arachidonic acid levels tend to be lower than those of breast-fed infants. It has been pointed out (Omoto: Journal of Japan Pediatric Society 1990; 94: 224-234). In addition, a decrease in arachidonic acid content in plasma and tissues was observed in systems enriched with fish oil and cholesterol (Garg et al: Li.
pids 1989; 24; 226-270).
【０００５】このように、アラキドン酸、ＤＨＡ及び／
又はコレステロールの同時強化に成功した例は知られて
いないのが技術の現状である。Thus, arachidonic acid, DHA and / or
Alternatively, it is the current state of the art that no example of successful simultaneous enhancement of cholesterol is known.
【０００６】[0006]
【発明が解決しようとする課題】本発明は、上記した技
術の現状に鑑みてなされたものであって、発明が解決し
ようとする具体的課題は次のとおりである。The present invention has been made in view of the current state of the art described above, and the concrete problems to be solved by the invention are as follows.
【０００７】（１）新生児期には、ｎ−３系列とｎ−６
系列の多価不飽和脂肪酸を強化する必要があり、しかも
そのバランス、つまりｎ−３系列／ｎ−６系列脂肪酸比
率（ω−３多価不飽和脂肪酸／ω−６多価不飽和脂肪酸
の比）も重要である。 （２）魚油を添加した場合、乳児期に必須であるといわ
れているコレステロールの血漿におけるレベルが低下す
る傾向にあり、また、魚油に含有されているＤＨＡ及び
ＥＰＡには脂肪酸不飽和活性を低下させる作用があり、
食餌性ｎ−６系列脂肪酸であるリノール酸からの供給で
は円滑に同系列脂肪酸であるアラキドン酸への代謝がな
されなくなる。 （３）更に、コレステロールも脂肪酸不飽和活性を抑制
する作用があり、したがって、ＤＨＡ及びコレステロー
ルの同時強化を目的として魚油とコレステロールを一緒
に供給すれば、アラキドン酸が充分に代謝されないこと
になる。 （４）しかも、アラキドン酸を含有する食品は動物性の
脂質などごく限られたものであり、しかもその含有量も
低い場合が多く、したがって食品からアラキドン酸を必
要量摂取することは困難であるし、ましてや高い安全性
とデリケートな風味が更に要求される乳児用食品として
このような食品を使用するには更に大きな困難性が存す
る。(1) In the neonatal period, n-3 series and n-6
It is necessary to strengthen the series of polyunsaturated fatty acids, and the balance thereof, that is, the n-3 series / n-6 series fatty acid ratio (ratio of ω-3 polyunsaturated fatty acid / ω-6 polyunsaturated fatty acid )It is also important. (2) When fish oil is added, the plasma level of cholesterol, which is said to be essential in infancy, tends to decrease, and the fatty acid unsaturated activity of DHA and EPA contained in fish oil decreases. Has the effect of
When linoleic acid, which is a dietary n-6 series fatty acid, is supplied, metabolism to arachidonic acid, which is a series fatty acid, is not smoothly performed. (3) Further, cholesterol also has an action of suppressing fatty acid unsaturated activity, and therefore, if fish oil and cholesterol are supplied together for the purpose of simultaneous enhancement of DHA and cholesterol, arachidonic acid will not be sufficiently metabolized. (4) Moreover, foods containing arachidonic acid are very limited such as animal lipids, and their content is often low, so it is difficult to take the required amount of arachidonic acid from foods. However, there is an even greater difficulty in using such foods as baby foods, which require further high safety and delicate flavor.
【０００８】したがって、本発明の目的は、これらの諸
問題を解決し、アラキドン酸、ＤＨＡ及び／又はコレス
テロールの同時強化、しかもバランスのとれた強化を行
い、安全性も高く、風味、食感、外観等にもすぐれた乳
児用食品を新たに創製することである。Therefore, the object of the present invention is to solve these problems, to simultaneously enhance arachidonic acid, DHA and / or cholesterol at the same time, and to achieve a balanced enhancement. The goal is to create new baby food products that have an excellent appearance.
【０００９】[0009]
【課題を解決するための手段】本発明者らは、上記した
ように、各要件の２つについてすらもこれらを両立させ
ることが困難でありましてや３つ以上併立させることは
きわめて困難である各要件を同時に満足させるため鋭意
研究を行った結果、魚油とヌクレオチドとを配合した食
餌が生体内においてアラキドン酸、ＤＨＡを増加させ、
なおかつコレステロールを減少させないという有用な新
知見を得た。As described above, it is difficult for the present inventors to satisfy both of the two requirements, and it is extremely difficult to arrange three or more of them. As a result of intensive studies to satisfy the requirements at the same time, a diet containing fish oil and nucleotides increases arachidonic acid and DHA in vivo,
Moreover, we obtained a useful new finding that cholesterol is not reduced.
【００１０】そして更に検討の結果、魚油と核酸との配
合食は、安全性にも問題がないばかりか、風味、食感、
外観においてもきわめてすぐれており、乳児用食品とし
て好適であること、また育児用調製乳にも適用可能であ
ることも確認し、これらの有用新知見に基づき更に研究
した結果、本発明は遂に完成されたものである。以下、
本発明について詳述する。As a result of further studies, the combination food of fish oil and nucleic acid has not only a safety problem but also a flavor, texture,
The appearance was also extremely excellent, and it was confirmed that it is suitable as a food for infants, and that it can also be applied to infant formula, and as a result of further research based on these useful new findings, the present invention was finally completed. It was done. Less than,
The present invention will be described in detail.
【００１１】すなわち本発明は、アラキドン酸、ＤＨＡ
及び／又はコレステロールを含有する食用油脂とヌクレ
オチドとを配合してなる乳児用食品を基本的技術思想と
するものである。本発明に係る乳児用食品を摂取するこ
とにより、生体内においてアラキドン酸及びＤＨＡを増
加させ、なおかつ血漿コレステロールを減少させること
がないという著効が奏され、本発明は、乳児のＤＨＡは
もとより、血漿コレステロール及び組織長鎖脂肪酸、特
に供給源の少ないアラキドン酸を増強するのにはじめて
成功したものである。以下、本発明を具体的に説明す
る。That is, the present invention relates to arachidonic acid, DHA
The basic technical idea is a food for infants, which is obtained by mixing an edible oil / fat containing cholesterol and / or cholesterol with a nucleotide. By ingesting the baby food according to the present invention, arachidonic acid and DHA in vivo is increased, and yet markedly effective without reducing plasma cholesterol, the present invention, not only DHA of the baby, It was the first to succeed in enhancing plasma cholesterol and tissue long-chain fatty acids, especially arachidonic acid, which has a low source. Hereinafter, the present invention will be described specifically.
【００１２】[0012]
【発明の実施の形態】本発明においては、食用油脂とヌ
クレオチドとを配合するが、食用油脂としては、動植物
由来の液状、半固体状、固体状の油脂がすべて使用する
ことができ、また、水素添加処理、分子蒸留処理、分別
処理等各種処理した油脂も使用することができる。食用
油脂の非限定例としては、次のものが挙げられる：魚
油、牛脂、豚脂、乳脂、羊脂、馬油、肝油、卵油、大豆
油、コーン油、パーム油、パーム核油、ヤシ油、米油、
菜種油、綿実油、シソ油、ゴマ油、紅花油、落花生油
等。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, edible oils and fats and nucleotides are blended. As the edible oils and fats, animal and plant-derived liquids, semisolids, and solid oils and fats can all be used. Oils and fats that have been subjected to various treatments such as hydrogenation treatment, molecular distillation treatment, and fractionation treatment can also be used. Non-limiting examples of edible oils and fats include: fish oil, beef tallow, lard, milk fat, sheep fat, horse oil, liver oil, egg oil, soybean oil, corn oil, palm oil, palm kernel oil, palm. Oil, rice oil,
Rapeseed oil, cottonseed oil, perilla oil, sesame oil, safflower oil, peanut oil, etc.
【００１３】これらの食用油脂は、いずれも本発明にお
いて使用できるが、ＤＨＡやコレステロール含量の高い
魚油は特に好適な食用油脂の１例である。本発明に用い
る魚油としては、一般に使用されている魚油でよく、例
えば、マグロ油、カツオ油、イワシ油、サバ油、サンマ
油、スケトウダラ油等が使用され、また、これらの混合
油または濃縮油を用いることができるが、乳児用調製乳
へはＤＨＡ含有量が高いマグロ油やカツオ油が好まし
い。Although any of these edible oils and fats can be used in the present invention, DHA and fish oil having a high cholesterol content are examples of particularly suitable edible oils and fats. The fish oil used in the present invention may be a commonly used fish oil, for example, tuna oil, bonito oil, sardine oil, mackerel oil, saury oil, walleye pollack oil, etc. are used, and also mixed oils or concentrated oils thereof. Can be used, but tuna oil or bonito oil having a high DHA content is preferable for infant formula.
【００１４】このような食用油脂は、１種類又は２種類
以上をヌクレオチドとともに使用する。食用油脂として
は、ＤＨＡ、コレステロール、アラキドン酸含量の高い
油脂が好適であるが、これらのすべてに富んだ油脂がな
い場合には、各成分の１つあるいは２つの含量の高い油
脂を選択し、これらを併用してもよい。また、必要ある
場合には、食用油脂を濃縮、分子蒸留、分別等の処理に
付して、各成分含量を高め、このようにして処理した食
用油脂を使用してもよい。Such edible oils and fats are used alone or in combination with two or more nucleotides. As edible fats and oils, DHA, cholesterol, fats and oils with a high arachidonic acid content are suitable, but when there is no fat or oil rich in all of them, one or two fats with a high content of each component are selected, These may be used in combination. If necessary, the edible oils and fats may be subjected to treatments such as concentration, molecular distillation, and fractionation to increase the content of each component, and the edible oils and fats thus treated may be used.
【００１５】例えば、魚油等の油脂を常法にしたがって
分子蒸留したり分別処理したりしてＤＨＡ濃度を高めた
り、炭酸ガス等の超臨界ガスを用いて魚油のコレステロ
ールを濃縮したりすること（特開昭６１−２６１３９８
号公報）も可能であるし、各成分を直接添加して油脂の
強化を行うことももちろん可能である。この場合、各成
分は精製品を直接添加してもよいし、アラキドン酸の場
合には大豆レシチンを使用するといったように各成分の
含有物を添加使用してもよい。For example, to increase the DHA concentration by molecularly distilling or fractionating oils and fats such as fish oil according to a conventional method, or to concentrate cholesterol in fish oil by using supercritical gas such as carbon dioxide gas ( JP-A-61-261398
Publication), and it is of course possible to directly add each component to strengthen the fats and oils. In this case, each component may directly add a purified product, or in the case of arachidonic acid, may use the content of each component such as using soybean lecithin.
【００１６】食用油脂におけるこれらの各成分の含有量
は、粉体１００ｇあたり、アラキドン酸４．９〜６０ｍ
ｇ、ＤＨＡ ２４．５〜２５０ｍｇ、コレステロール５
６〜１５０ｍｇとするのが良い。含有量の調節は、その
添加量、使用油脂における本来の含有量、濃縮処理条件
のコントロール等によって適宜行うことができる。The content of each of these components in the edible oil / fat is 4.9 to 60 m of arachidonic acid per 100 g of powder.
g, DHA 24.5-250 mg, cholesterol 5
6 to 150 mg is recommended. The content can be appropriately adjusted by controlling the amount added, the original content in the used fats and oils, the conditions of the concentration treatment, and the like.
【００１７】このような食用油脂はヌクレオチドととも
に乳児用食品に配合するが、ヌクレオチドとしては、シ
チジン−モノリン酸（ＣＭＰ）、ウリジン−モノリン酸
（ＵＭＰ）、アデノシン−モノリン酸（ＡＭＰ）、グア
ノシン−モノリン酸（ＧＭＰ）、イノシン−モノリン酸
（ＩＭＰ）の１種類以上を含んでなるヌクレオチド混合
物が使用される。その配合量は、粉体１００ｇ中に、Ｃ
ＭＰ ５〜１１ｍｇ、ＵＭＰ ２〜８ｍｇ、ＡＭＰ ０
〜１７ｍｇ、ＧＭＰ １〜１０ｍｇ及び／又はＩＭＰ
１〜６ｍｇとするのが良い。Such edible oils and fats are added to infant foods together with nucleotides. As nucleotides, cytidine-monophosphate (CMP), uridine-monophosphate (UMP), adenosine-monophosphate (AMP), guanosine-monophosphate are used. A mixture of nucleotides comprising one or more of acid (GMP), inosine-monophosphate (IMP) is used. The compounding amount is C in 100 g of powder.
MP 5-11 mg, UMP 2-8 mg, AMP 0
-17 mg, GMP 1-10 mg and / or IMP
It is good to use 1 to 6 mg.
【００１８】このようにして調製した食用油脂及びヌク
レオチドは、これを各種の飲料、食品に配合することに
より、乳児用食品を自由に製造することができる。本発
明に係る乳児用食品（飲料も包含される）は、風味、食
感、外観等において問題はなく、調製乳等の乳製品のほ
か、離乳食、健康食、健康ドリンク等各種の形態とする
ことができ、乳幼児はもとより、成人、健常者、病弱
者、老人等の飲食品としても有利に利用できる。The edible oils and fats and nucleotides thus prepared can be freely produced as infant foods by blending them with various beverages and foods. The baby food (including beverages) according to the present invention has no problems in flavor, texture, appearance, etc., and is in various forms such as baby foods, healthy foods, healthy drinks in addition to dairy products such as modified milk. In addition to infants, it can be advantageously used as food and drink for adults, healthy people, sick people, old people and the like.
【００１９】本発明に係る乳児用食品として調製乳を調
製するには、例えば次のようにして行えばよい。すなわ
ち、脱脂乳、牛乳カゼイン、牛乳脱塩ホエイタンパク
質、乳糖、オリゴ糖、ショ糖およびデキストリンを温湯
に溶解混合後、ビタミン・ミネラル類（例えば、ビタミ
ンＢ1、ビタミンＢ2、ビタミンＢ6、Ｌ−アスコルビン
酸ナトリウム、パントテン酸カルシウム、ナイアシン、
葉酸、クエン酸第一鉄ナトリウム、硫酸第一鉄もしくは
ピロリン酸第二鉄、塩化カリウム、塩化ナトリウム、炭
酸カルシウム、硫酸マグネシウムもしくは塩化マグネシ
ウム、硫酸銅、硫酸亜鉛など）を溶解した水溶液を加
え、水相部とする。この溶液に、アラキドン酸／ＤＨＡ
／コレステロール高含有油脂及びヌクレオチドを加え、
ホモミキサーにて混合し、ホモジナイザーで均質化す
る。得られた乳化液を常法により殺菌、濃縮、噴霧乾燥
して調製粉乳とする。この調製粉乳を温湯に溶解し約６
〜８倍に希釈して調乳する。To prepare the modified milk as the baby food according to the present invention, for example, the following may be carried out. That is, skim milk, milk casein, milk demineralized whey protein, lactose, oligosaccharides, sucrose and dextrin are dissolved and mixed in warm water, and then vitamins and minerals (for example, vitamin B 1 , vitamin B 2 , vitamin B 6 , L -Sodium ascorbate, calcium pantothenate, niacin,
Folic acid, sodium ferrous citrate, ferrous sulfate or ferric pyrophosphate, potassium chloride, sodium chloride, calcium carbonate, magnesium sulfate or magnesium chloride, copper sulfate, zinc sulfate, etc. Aibe. To this solution, arachidonic acid / DHA
/ Add fats and nucleotides high in cholesterol and nucleotides,
Mix with a homomixer and homogenize with a homogenizer. The obtained emulsion is sterilized, concentrated and spray-dried by a conventional method to prepare a powdered milk. Dissolve this modified milk powder in warm water for about 6
~ 8-fold diluted to prepare milk.
【００２０】以下、本発明を実施例によって具体的に説
明する。The present invention will be specifically described below with reference to examples.
【００２１】[0021]
【実施例１】ヌクレオチド及び魚油摂取離乳ラットにお
ける血漿脂質及び肝臓脂肪酸組成に及ぼす影響につい
て、３週齢ＳＤ系ラットを用いて検討した。[Example 1] The effects on plasma lipids and liver fatty acid composition in weanling rats fed with nucleotides and fish oil were examined using 3-week-old SD rats.
【００２２】すなわち、ラット１０頭ずつを次のＡ〜Ｄ
群でそれぞれ３週間飼育した。 Ａ群（対照食）：いずれも強化していない対照食（市販
の実験動物用飼料のみ） Ｂ群（魚油食）：アラキドン酸 ４．９ｍｇ／１００
ｇ、ＤＨＡ ２４．５ｍｇ／１００ｇ、コレステロール
１０．５ｍｇ／１００ｇを強化した魚油食 Ｃ群（核酸食）：ＣＭＰ ６．０１ｍｇ／１００ｇ、Ｕ
ＭＰ ３．８５ｍｇ／１００ｇ、ＡＭＰ ０．２１ｍｇ
／１００ｇ、ＧＭＰ １．５５ｍｇ／１００ｇ、ＩＭＰ
３．０７ｍｇ／１００ｇを添加した核酸食 Ｄ群（核酸＋魚油食）：核酸及び魚油を強化した核酸魚
油食That is, 10 rats each are
Each group was raised for 3 weeks. Group A (control diet): Control diet without any fortification (commercial animal feed only) Group B (fish oil diet): Arachidonic acid 4.9 mg / 100
g, DHA 24.5 mg / 100 g, cholesterol 10.5 mg / 100 g fortified fish oil diet Group C (nucleic acid diet): CMP 6.01 mg / 100 g, U
MP 3.85mg / 100g, AMP 0.21mg
/ 100g, GMP 1.55mg / 100g, IMP
Nucleic acid diet with 3.07 mg / 100 g added Group D (nucleic acid + fish oil diet): Nucleic acid and fish oil enriched nucleic acid fish oil diet
【００２３】３週間飼育した後、ヘパリン血漿を超遠心
分離機を用いてリポ蛋白質画分に分離し、酵素法にてリ
ポ蛋白質脂質含量を分析した。また、肝臓脂質をＴＬＣ
を用いてリン脂質画分に分離し、ガスクロマトグラフィ
ーにて脂肪酸組成を分析した。血漿総、ＶＬＤＬ、ＬＤ
Ｌ及びＨＤＬ画分コレステロール（ＣＨ）含量を下記表
１に、そして肝臓フォスファチジルコリン（ＰＣ）、フ
ォスファチジルエタノールアミン（ＰＥ）の脂肪酸組成
（２０：４ ｎ−６（アラキドン酸）及び２２：６ ｎ
−３（ドコサヘキサエン酸））を下記表２に示した。After breeding for 3 weeks, heparin plasma was separated into lipoprotein fractions using an ultracentrifuge and the lipoprotein lipid content was analyzed by the enzymatic method. In addition, TLC
Was separated into phospholipid fractions and the fatty acid composition was analyzed by gas chromatography. Total plasma, VLDL, LD
The cholesterol (CH) content of the L and HDL fractions is shown in Table 1 below, and the fatty acid composition (20: 4 n-6 (arachidonic acid) and 22 of liver phosphatidylcholine (PC), phosphatidylethanolamine (PE). : 6 n
-3 (docosahexaenoic acid)) is shown in Table 2 below.
【００２４】[0024]
【表１】 [Table 1]
【００２５】[0025]
【表２】 [Table 2]
【００２６】上記結果から明らかなように、血漿ＬＤＬ
−コレステロールはＡ群に対してＢ群では減少している
が、Ｄ群では減少せず、Ａ群の値を維持している。ま
た、肝臓フォスファチジルコリンアラキドン酸含量はＡ
群に対してＣ群にて増加していることが認められた。As is clear from the above results, plasma LDL
-Cholesterol is decreased in group B compared to group A, but is not decreased in group D, and the value of group A is maintained. The liver phosphatidylcholine arachidonic acid content is A
It was observed that the increase was observed in group C relative to the group.
【００２７】[0027]
【実施例２】ヌクレオチド及び魚油摂取哺乳ラットにお
ける血漿脂質及び肝臓脂肪酸組成に及ぼす影響につい
て、８日齢ＳＤ系ラットを用いて検討した。[Example 2] The effects on plasma lipids and liver fatty acid composition in feeding rats fed with nucleotides and fish oil were examined using 8-day-old SD rats.
【００２８】すなわち、ラット１０頭ずつを次のＡ〜Ｄ
群でそれぞれ１０日間哺育した。 Ａ群（対照乳）：いずれも強化していない対照乳（市販
の実験動物用飼育乳のみ） Ｂ群（魚油乳）：アラキドン酸 ８．２ｍｇ／１００ｍ
ｌ、ＤＨＡ ３３．６ｍｇ／１００ｍｌを強化した魚油
乳 Ｃ群（核酸乳）：ＣＭＰ １．４３ｍｇ／１００ｍｌ、
ＵＭＰ ０．９９ｍｇ／１００ｍｌ、ＡＭＰ ２．２９
ｍｇ／１００ｍｌ、ＧＭＰ １．３０ｍｇ／１００ｍ
ｌ、ＩＭＰ ０．７８ｍｇ／１００ｍｌを強化した核酸
乳 Ｄ群（核酸＋魚油乳）：核酸及び魚油を強化した核酸魚
油乳That is, 10 rats each are
Each group was fed for 10 days. Group A (control milk): Control milk without any fortification (only commercially available experimental animal-fed milk) Group B (fish oil milk): Arachidonic acid 8.2 mg / 100 m
1, fish oil milk fortified with DHA 33.6 mg / 100 ml Group C (nucleic acid milk): CMP 1.43 mg / 100 ml,
UMP 0.99 mg / 100 ml, AMP 2.29
mg / 100 ml, GMP 1.30 mg / 100 m
l, Nucleic acid milk fortified with IMP 0.78 mg / 100 ml Group D (nucleic acid + fish oil milk): Nucleic acid and fish oil fortified nucleic acid fish oil milk
【００２９】１０日間哺育した後、実施例１と同様にし
て、ラットの血漿リポ蛋白質コレステロール含量及び肝
臓リン脂質脂肪酸組成を分析した。血漿総、ＶＬＤＬ、
ＬＤＬ及びＨＤＬ画分ＣＨ含量を下記表３に、そして肝
臓ＰＣ、ＰＥの脂肪酸組成（アラキドン酸、ＤＨＡ）を
下記表４に示した。After lactating for 10 days, the plasma lipoprotein cholesterol content and liver phospholipid fatty acid composition of the rat were analyzed in the same manner as in Example 1. Total plasma, VLDL,
The CH content of LDL and HDL fractions is shown in Table 3 below, and the fatty acid composition of liver PC and PE (arachidonic acid, DHA) is shown in Table 4 below.
【００３０】[0030]
【表３】 [Table 3]
【００３１】[0031]
【表４】 [Table 4]
【００３２】上記結果から明らかなように、血漿ＬＤＬ
−コレステロールはＡ群に対してヌクレオチドを強化し
たＣ群およびＤ群で高かった（ｐ＜０．０５）。また、
血漿ＨＤＬ−コレステロールはＡ群に対してＢ群では低
くなっているのに、Ｄ群ではＡ群の値を維持しているこ
とが認められた。肝臓フォスファチジルエタノールアミ
ンアラキドン酸はＡ群に対してＣ群にて高く、肝臓フォ
スファチジルコリンアラキドン酸でも、Ｃ群は増加して
いることが認められた。さらに、Ｂ群ではアラキドン酸
含量が低下しているが、Ｄ群ではＡ群と同程度の値を維
持した。ＤＨＡでもフォスファチジルエタノールアミン
画分でＣ群ではＡ群に対して、同程度なのに対して、Ｄ
群ではＢ群と同程度の高い値を示した。As is clear from the above results, plasma LDL
-Cholesterol was higher in nucleotide-enriched groups C and D compared to group A (p <0.05). Also,
It was found that plasma HDL-cholesterol was lower in group B than in group A, but the value of group A was maintained in group D. It was confirmed that liver phosphatidylethanolamine arachidonic acid was higher in group C than in group A, and liver phosphatidylcholine arachidonic acid was also increased in group C. Furthermore, although the arachidonic acid content was reduced in group B, the value in group D was maintained at the same level as in group A. In DHA, the phosphatidylethanolamine fraction was similar in Group C to Group A, whereas
The value of the group was as high as that of the group B.
【００３３】[0033]
【実施例３】製品粉体１００ｇ当り、アラキドン酸４．
９ｍｇ、ＤＨＡ ２４．５ｍｇ、コレステロール５６．
０ｍｇ、更に、ＣＭＰ ６．０１ｍｇ、ＵＭＰ ３．８
５ｍｇ、ＡＭＰ ０．２１ｍｇ、ＧＭＰ １．５５ｍ
ｇ、ＩＭＰ ３．０７ｍｇとなるように、市販の育児用
調製粉乳の原料精製魚油２５ｇを強化し、強化魚油を調
製した。脱脂乳８０ｇ、カゼイン４ｇ、乳清たん白質１
８ｇ、糖質４０ｇ、ミネラル０．７ｇ、ビタミン０．７
ｇを添加混合し、ｐＨ調整後、殺菌、濃縮した液に、油
脂として上記した強化魚油２５ｇを混合し、均質化後、
噴霧乾燥して乾燥製品を得た。また、均質化後、噴霧乾
燥することなく、液状製品を調製した。[Example 3] 4. Arachidonic acid per 100 g of product powder
9 mg, DHA 24.5 mg, cholesterol 56.
0 mg, further CMP 6.01 mg, UMP 3.8
5mg, AMP 0.21mg, GMP 1.55m
g, IMP 3.07 mg, 25 g of purified fish oil as a raw material of commercially available infant formula was fortified to prepare fortified fish oil. 80 g skim milk, 4 g casein, 1 whey protein
8g, sugar 40g, mineral 0.7g, vitamin 0.7
25 g of the above-mentioned fortified fish oil as an oil and fat was mixed with a liquid obtained by sterilizing and concentrating after adding and mixing g, pH adjustment, and homogenizing,
Spray dried to obtain a dried product. After homogenization, a liquid product was prepared without spray drying.
【００３４】[0034]
【発明の効果】本発明の乳児用食品を用いることによ
り、乳児にとって必須であるといわれるｎ−３系列多価
不飽和脂肪酸であるＤＨＡとｎ−６系列多価不飽和脂肪
酸であるアラキドン酸を組織中にバランスよく増加させ
ることができ、さらに、魚油摂取による血漿コレステロ
ールの減少を抑制し、乳児にとって適切な生体内脂質バ
ランスを保つことができる。EFFECTS OF THE INVENTION By using the baby food of the present invention, DHA, which is an n-3 series polyunsaturated fatty acid and arachidonic acid, which is an n-6 series polyunsaturated fatty acid, which are said to be essential for infants, are added. It can be balancedly increased in tissues, and further, the decrease of plasma cholesterol due to fish oil intake can be suppressed, and an appropriate in vivo lipid balance can be maintained for infants.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 松本 薫 東京都東村山市栄町１−21−３ 明治乳業 株式会社栄養科学研究所内 (72)発明者 米久保 明得 東京都東村山市栄町１−21−３ 明治乳業 株式会社栄養科学研究所内 (72)発明者 桑田 有 東京都東村山市栄町１−21−３ 明治乳業 株式会社栄養科学研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Kaoru Matsumoto 1-21-3 Sakaemachi, Higashimurayama City, Tokyo Meiji Dairy Co., Ltd., Institute of Nutritional Sciences (72) Inventor Akito Yonekubo 1-21 Sakaemachi, Higashimurayama City, Tokyo 3 Meiji Dairy Industry Co., Ltd. Nutrition Science Research Institute (72) Inventor Yu Kuwata 1-21-3 Sakaemachi, Higashimurayama City, Tokyo Meiji Dairy Co., Ltd. Nutrition Science Research Institute
Claims (5)
高含有食用油脂と、ヌクレオチドとを配合してなるこ
と、を特徴とする乳児用食品。1. An infant food characterized by comprising arachidonic acid / DHA / edible cholesterol-rich edible oil / fat and a nucleotide.
５〜１１ｍｇ、ウリジン−モノリン酸２〜８ｍｇ、アデ
ノシン−モノリン酸０〜１７ｍｇ、グアノシン−モノリ
ン酸１〜１０ｍｇ及び／又はイノシン−モノリン酸１〜
６ｍｇと、アラキドン酸を粉体１００ｇあたり４．９〜
６０ｍｇ、ＤＨＡを２４．５〜２５０ｍｇ及びコレステ
ロールを５６〜１５０ｍｇ含有した食用油脂を配合して
なること、を特徴とする血漿コレステロール増加作用及
び／又は組織内多価不飽和脂肪酸増加作用を有する乳児
用食品。2. Cytidine-monophosphate 5-11 mg, uridine-monophosphate 2-8 mg, adenosine-monophosphate 0-17 mg, guanosine-monophosphate 1-10 mg and / or inosine-monophosphate 1-g in 100 g of powder.
6 mg and arachidonic acid 4.9-per 100 g powder
60 mg, 24.5 to 250 mg of DHA and 56 to 150 mg of cholesterol are added to the mixture of edible oils and fats, and the effect of increasing plasma cholesterol and / or the effect of increasing polyunsaturated fatty acids in tissues is for infants. Food.
５〜１１ｍｇ、ウリジン−モノリン酸２〜８ｍｇ、アデ
ノシン−モノリン酸０〜１７ｍｇ、グアノシン−モノリ
ン酸１〜１０ｍｇ及びイノシン−モノリン酸１〜６ｍｇ
からなるヌクレオチド混合物と、アラキドン酸を粉体１
００ｇあたり４．９〜６０ｍｇ、ＤＨＡを２４．５〜２
５０ｍｇ及びコレステロールを５６〜１５０ｍｇ含有し
た食用油脂を配合してなること、を特徴とする血漿コレ
ステロール及び組織内多価不飽和脂肪酸増加作用を有す
る乳児用食品。3. Cytidine-monophosphate 5-11 mg, uridine-monophosphate 2-8 mg, adenosine-monophosphate 0-17 mg, guanosine-monophosphate 1-10 mg and inosine-monophosphate 1-6 mg in 100 g of the powder.
A mixture of nucleotides and arachidonic acid powder 1
4.9-60 mg / 00g, 24.5-2 DHA
An edible oil / fat containing 50 mg and cholesterol of 56 to 150 mg is blended, and an infant food having an effect of increasing plasma cholesterol and tissue polyunsaturated fatty acids.
徴とする請求項１〜３のいずれか１項に記載の乳児用食
品。4. The baby food according to any one of claims 1 to 3, wherein fish oil is included in the edible fats and oils.
を特徴とする請求項１〜４のいずれか１項に記載の乳児
用食品。5. The baby food is infant formula.
The food for infants according to any one of claims 1 to 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12633296A JP3627043B2 (en) | 1996-04-24 | 1996-04-24 | n-6 series / n-3 series fatty acid balance improved nucleotide-containing baby food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12633296A JP3627043B2 (en) | 1996-04-24 | 1996-04-24 | n-6 series / n-3 series fatty acid balance improved nucleotide-containing baby food |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09285267A true JPH09285267A (en) | 1997-11-04 |
| JP3627043B2 JP3627043B2 (en) | 2005-03-09 |
Family
ID=14932571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12633296A Expired - Fee Related JP3627043B2 (en) | 1996-04-24 | 1996-04-24 | n-6 series / n-3 series fatty acid balance improved nucleotide-containing baby food |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3627043B2 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000060424A (en) * | 1998-08-19 | 2000-02-29 | Meiji Milk Prod Co Ltd | Infant food composition adjusted with phospholipid and fatty acid composition |
| WO2000051444A1 (en) * | 1999-03-04 | 2000-09-08 | Suntory Limited | Utilization of material containing docosapentaenoic acid |
| WO2001043570A1 (en) * | 1999-12-17 | 2001-06-21 | Wyeth | Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome |
| EP1666092A2 (en) * | 2001-04-30 | 2006-06-07 | Trommsdorff GmbH & Co.KG Arzneimittel | Drug combination comprising a fatty acid and a uridine compound. |
| US7141266B2 (en) * | 1998-05-21 | 2006-11-28 | Beech-Nut Nutrition Corporation | Baby-food compositions enhancing visual acuity and methods therefor |
| US7413759B2 (en) | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
| US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US10086009B2 (en) | 2005-05-23 | 2018-10-02 | Massachusetts Institute Of Technologies | Compositions containing pufa and/or uridine and methods of use thereof |
| CN113615745A (en) * | 2021-08-19 | 2021-11-09 | 桦南农盛园食品有限公司 | Blending method of nutrition supplementing blend oil and product |
-
1996
- 1996-04-24 JP JP12633296A patent/JP3627043B2/en not_active Expired - Fee Related
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141266B2 (en) * | 1998-05-21 | 2006-11-28 | Beech-Nut Nutrition Corporation | Baby-food compositions enhancing visual acuity and methods therefor |
| US7413759B2 (en) | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
| US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| JP2000060424A (en) * | 1998-08-19 | 2000-02-29 | Meiji Milk Prod Co Ltd | Infant food composition adjusted with phospholipid and fatty acid composition |
| US6596766B1 (en) | 1999-03-04 | 2003-07-22 | Suntory Limited | Utilization of material containing docosapentaenoic acid |
| JP4518674B2 (en) * | 1999-03-04 | 2010-08-04 | サントリーホールディングス株式会社 | Use of docosapentaenoic acid-containing substances |
| WO2000051444A1 (en) * | 1999-03-04 | 2000-09-08 | Suntory Limited | Utilization of material containing docosapentaenoic acid |
| WO2001043570A1 (en) * | 1999-12-17 | 2001-06-21 | Wyeth | Composition for improving the proliferative response during adaptation of the gastrointestinal tract and use in short bowel syndrome |
| EP1666092A2 (en) * | 2001-04-30 | 2006-06-07 | Trommsdorff GmbH & Co.KG Arzneimittel | Drug combination comprising a fatty acid and a uridine compound. |
| EP1666092A3 (en) * | 2001-04-30 | 2006-11-29 | Trommsdorff GmbH & Co.KG Arzneimittel | Drug combination comprising a fatty acid and a uridine compound. |
| US10086009B2 (en) | 2005-05-23 | 2018-10-02 | Massachusetts Institute Of Technologies | Compositions containing pufa and/or uridine and methods of use thereof |
| US10525071B2 (en) | 2005-05-23 | 2020-01-07 | Massachusets Institue Of Technology | Compositions containing PUFA and methods of use thereof |
| US10736912B2 (en) | 2005-05-23 | 2020-08-11 | Massachusetts Institute Of Technology | Compositions containing PUFA and/or uridine and methods of use thereof |
| CN113615745A (en) * | 2021-08-19 | 2021-11-09 | 桦南农盛园食品有限公司 | Blending method of nutrition supplementing blend oil and product |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3627043B2 (en) | 2005-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3113015B2 (en) | Fat mixtures for infant and adult nutrition | |
| US20150079225A1 (en) | Nutritional composition | |
| JP3195594B2 (en) | A food composition containing a milk-derived phospholipid. | |
| KR20060030860A (en) | Infant formula | |
| PT94459A (en) | Process for the preparation of a stabilized fat mixture for the preparation of foodstuffs | |
| US10039805B1 (en) | Infant formulas having vitamin complexes with enhanced bioavailability | |
| JPH08205769A (en) | Strengthened or reinforced milk or milk induction product | |
| EP2247199A1 (en) | Methods and compositions for the treatment of bone conditions | |
| CN103687495A (en) | Composition comprising vitamin k2 | |
| US20090099261A1 (en) | Omega-3 mixtures | |
| CN105188411A (en) | Method of enhancing bioavailability of DHA and other lipid-soluble nutrients | |
| JP3576318B2 (en) | Nutrient composition containing nucleic acid-related substance | |
| JP3627043B2 (en) | n-6 series / n-3 series fatty acid balance improved nucleotide-containing baby food | |
| Kidd | Phospholipids: versatile nutraceuticals for functional foods | |
| JP4034370B2 (en) | Brain function improving agent and nutritional composition | |
| JPH11269074A (en) | Digestant for lipid | |
| EP2037757B1 (en) | Feed product for dairy cows and method of obtaining a dairy product | |
| JPH10327804A (en) | Nucleic acid-relating substance, dha, arachidonic acid and composition | |
| JP2001275614A (en) | Mammalian milk-derived phospholipid-containing oral composition | |
| JP2525624B2 (en) | Baby milk powder containing polyunsaturated fatty acids | |
| CN113660867A (en) | Nutritional composition exhibiting phase separation under gastric conditions and method of making the same | |
| JPH06169735A (en) | Nutritious drink composition | |
| JP2001029010A (en) | Nutrient composition | |
| MEYER et al. | Fate of the synergistic antioxidant system ascorbic acid, lecithin, and tocopherol in mayonnaise: partition of ascorbic acid | |
| JP2968751B2 (en) | Infant formula containing breast milk-like lipid composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040427 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040824 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041116 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041117 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131217 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |